Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes.
Fulminant type 1 diabetes (FT1D) is a distinct subtype of type 1 diabetes and is fatal without immediate diagnosis and treatment. At present, there are no biomarkers for early and predictive detection of FT1D.First, we analyzed a total of 6 serum samples from 3 patients with FT1D (1 sample in the ac...
Main Authors: | Fumitaka Haseda, Akihisa Imagawa, Hiroyoshi Nishikawa, Shinobu Mitsui, Chiharu Tsutsumi, Reiko Fujisawa, Hiroyuki Sano, Yuko Murase-Mishiba, Jungo Terasaki, Shimon Sakaguchi, Toshiaki Hanafusa |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4981355?pdf=render |
Similar Items
-
Possible contribution of taurine to distorted glucagon secretion in intra-islet insulin deficiency: a metabolome analysis using a novel α-cell model of insulin-deficient diabetes.
by: Megumi Bessho, et al.
Published: (2014-01-01) -
Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient‐derived induced pluripotent stem cells for future research
by: Yoshiya Hosokawa, et al.
Published: (2019-09-01) -
Re-Enlightenment of Fulminant Type 1 Diabetes under the COVID-19 Pandemic
by: Hiroyuki Sano, et al.
Published: (2022-11-01) -
Two types of fulminant type 1 diabetes mellitus: Immune checkpoint inhibitor‐related and conventional
by: Akihisa Imagawa
Published: (2021-06-01) -
CMRF: analyzing differential gene regulation in two group perturbation experiments
by: Bandyopadhyay Nirmalya, et al.
Published: (2012-04-01)